We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Global Critical Care Diagnostics Market to Reach USD 1.3 Billion by 2024

By LabMedica International staff writers
Posted on 19 Jul 2018
The global critical care diagnostics (CCD) market is estimated to have been valued at USD 837.6 million in 2015 and is expected to reach USD 1.3 billion by 2024, driven by increasing awareness among physicians, patients’ requirements for cost-efficient, rapid, and accurate diagnostic tests, and technological advancements. More...
However, the high costs of these tests and scarcity of skilled labor for handling new platforms pose a challenge to the market growth.

These are the latest findings of Grand View Research, Inc. (San Francisco, CA, USA), a market research and consulting company.

CCD tests deal with the specialized care and diagnosis of life-threatening diseases occurring in patients. Being cost-effective and easy-to-use with rapid and accurate diagnosis, they are used in emergency rooms, operating rooms, and intensive care units (ICUs) around the world. The CCD segment accounts for a share of 2-3% of the in-vitro diagnostic market.

The demand for CCD tests has been increasing due to growing awareness among patients about better healthcare options and increasing knowledge of target therapy among physicians. Based on type, the CCD market is being driven mainly by the clinical chemistry, flow cytometry tests, and coagulation tests segments. The immunoproteins segment is estimated to account for the largest share of the CCD market, in terms of value, due to a rise in the demand for rapid and accurate early diagnosis as well as the ability to reduce the recovery time of patients. However, microbiology and infectious tests along with immunoproteins assays are estimated to drive the CCD market, by type, during the forecast period.

Hospital ancillary locations, such as emergency rooms, operating rooms, and ICUs, among others, are the main end-users of CCDs. The growing adoption of telehealth and increasing awareness of advanced diagnostics tools has also influenced the market growth. The emergency rooms segment is expected to drive the growth of the CCD market, by end-user, during the forecast period.

Geographically, North America is estimated to hold the largest share of the global CCD market, followed by Europe. However, the CCD market in Asia Pacific is expected to register the highest growth during the forecast period, driven by the region’s increasing geriatric population, growing number of intensive care specialized hospitals in India, and improved healthcare infrastructure in the rural areas. Additionally, new health reforms implemented by the government in China have expanded the insurance coverage of patients and improved the country’s primary healthcare system, further aiding the growth of the CCD market in Asia Pacific.

Related Links:
Grand View Research


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.